Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.
about
Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entryLoss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.HIV-1 transmission biology: selection and characteristics of infecting viruses.Characterization of HIV-1 envelopes in acutely and chronically infected injection drug usersEvolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.Viral determinants of HIV-1 macrophage tropism.Efficiency of CCR5 coreceptor utilization by the HIV quasispecies increases over time, but is not associated with disease progression.Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions.Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrinHIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domainsAdaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.The HIV-1 transmission bottleneck.Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions.
P2860
Q33769382-1FCC612B-92B5-44BE-B0D5-C7147A2E90D4Q33810849-83E1738F-E6E4-40E7-96D1-88B05ECFB326Q33961448-0CBC6630-9E7B-455A-8C88-89EF5B33ECA8Q34158525-39FE364C-E99D-4FEF-BC1F-4C97548BA445Q34620235-E43AAAD1-A15E-4170-9E9A-DA3A4F74FF42Q34757951-73AE91FF-8BF4-4E9F-9F83-DF1CE9064843Q34806205-62A9A6CD-898D-4CBA-BDA0-55224F91A1B9Q34906292-6D3A4527-872D-45B3-A751-A1DB61C06B98Q35018129-BAAB2676-F9F8-4FA4-A114-E352A4225040Q35060140-C272EB7A-ABDE-480B-BADC-20D21318FC49Q35071940-FE38FCBA-E646-4462-A41B-83AC61BAC0B3Q35593158-97D16A7F-E1B2-4324-AC52-6C1BA3959314Q35799147-E5EC0C9B-603E-4A28-B3AA-C84BCF4EB55FQ35842299-7D2D97C9-86D5-481B-81D0-2CACA2CC9A98Q36000722-4C6D6A4C-C5C6-4934-A6E3-D483B30966ACQ36305433-032EEDD4-F9FA-4533-9620-43BE6420D5D1Q36484034-1CCC0E40-BF3C-4C87-88EF-4CD3C77311C8Q37034798-7DB342FF-8A27-4E64-A2BF-D4589B4135EBQ37238727-856AB4D2-9C50-4B1F-98C9-0C7015C0ED50Q37444204-E07DC9CB-4998-4403-BEB6-2A07EC8C414FQ37547162-379689B8-EAAE-4DE4-A458-01901B794633Q38703060-CD4C0B23-631E-4F7C-9009-801B186F518FQ38909755-7E140B13-2DB5-4713-86DD-8035185D0BE1Q42314454-EBD18D27-9188-4702-84B5-623F09E76047Q42348438-5867D45B-64B6-4479-A915-A57038F1348CQ42638889-F1034AA8-6FB0-48B8-8904-9083855A50ACQ51450830-A74B6B35-AD93-4118-A72A-93DB27DB88AA
P2860
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human immunodeficiency virus t ...... se from early after infection.
@en
Human immunodeficiency virus t ...... se from early after infection.
@nl
type
label
Human immunodeficiency virus t ...... se from early after infection.
@en
Human immunodeficiency virus t ...... se from early after infection.
@nl
prefLabel
Human immunodeficiency virus t ...... se from early after infection.
@en
Human immunodeficiency virus t ...... se from early after infection.
@nl
P2093
P2860
P356
P1433
P1476
Human immunodeficiency virus t ...... ose from early after infection
@en
P2093
Angela Fellows
Anupa Kamat
Behzad Etemad
Sandra Lee
P2860
P304
P356
10.1128/JVI.00925-09
P407
P577
2009-07-22T00:00:00Z